Rapid outpatient low-dose initiation of buprenorphine for individuals with OUD using fentanyl
使用芬太尼对 OUD 患者进行快速门诊低剂量丁丙诺啡起始治疗
基本信息
- 批准号:10738961
- 负责人:
- 金额:$ 23.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-15 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:Absence of pain sensationAbstinenceAdherenceAffinityAftercareBuprenorphineCase SeriesCase StudyChronicClinicalClinical TrialsDoseDropoutDrug KineticsFentanylGoalsHeroinHospitalizationHospitalsHourHydromorphoneIllicit DrugsIndividualInpatientsLicensingMaintenanceMeasuresMethodologyMonitorMorbidity - disease rateNorfentanylNorth AmericaOpioid Receptor BindingOpioid agonistOutpatientsOverdoseParticipantPatientsPennsylvaniaPersonsPharmaceutical PreparationsPilot ProjectsPlasmaProcessProtocols documentationPublic HealthRandomizedRandomized, Controlled TrialsRegulationRelapseResearchRetrospective cohort studyRiskSafetySamplingSpeedSurveysTestingTherapeuticTimeUniversitiesUrineWithdrawalWorkaddictionarmbuprenorphine treatmentdesignefficacy testingexperiencefentanyl useimprovedinnovationinterestlipophilicitymortalitymu opioid receptorsnovelnovel strategiesopioid useopioid use disorderopioid withdrawaloverdose riskpilot trialpreventprimary care settingprimary outcomepublic health prioritiesrecruitsafety studysafety testingsecondary outcomesuccesssynthetic opioid
项目摘要
PROJECT SUMMARY
Opioid use disorder (OUD) involving fentanyl is a major public health problem. OUD treatment with
buprenorphine reduces all-cause mortality and drug-related morbidity and can be started by licensed
prescribers in any outpatient or inpatient setting. For individuals using fentanyl, the process of starting
buprenorphine is increasingly complicated by precipitated withdrawal. Withdrawal during initiation of
buprenorphine deters some individuals from starting treatment and has been associated with treatment drop-
out and relapse among those who do start. The goal of this project is to test the preliminary efficacy, safety,
feasibility, and acceptability of a novel approach to initiating buprenorphine treatment for OUD that can be used
in outpatient setting without requiring or precipitating opioid withdrawal. We will recruit 60 subjects with
untreated OUD and recent fentanyl use through the University of Pennsylvania's Center for the Studies of
Addiction. Subjects will be randomized to one of two arms: standard initiation, in which subjects will start
buprenorphine after >8 hours of abstinence once they develop moderate opioid withdrawal with Clinical Opiate
Withdrawal Scale (COWS) at least 11; or a novel low-dose (“micro-dose”) approach, which is started with
COWS<4 and where buprenorphine doses are escalated over 10 hours, without ongoing use of full-agonist
opioids. We will compare success rates with each approach, with “success” defined as reaching a total-daily
dose of 8 mg buprenorphine without an increase of >6 in COWS from baseline and without early termination
for any reason. Findings from this study will be used to support an R01 application to test this novel approach
to initiating buprenorphine in real-world, outpatient settings with a larger sample of individuals with untreated
OUD. This methodology has broad applications for increasing access to office-based treatment for OUD.
项目摘要
涉及芬太尼的阿片类药物使用障碍(OUD)是一个主要的公共卫生问题。OUD治疗,
丁丙诺啡可降低全因死亡率和药物相关发病率,
在任何门诊或住院环境中的处方者。对于使用芬太尼的个人来说,
丁丙诺啡因突然停药而变得越来越复杂。启动期间退出
丁丙诺啡阻止一些人开始治疗,并与治疗下降有关-
在那些已经开始的人中退出和复发。本项目的目的是测试初步的有效性,安全性,
可行性和可接受性的一种新的方法,开始丁丙诺啡治疗OUD,
不需要或促使阿片类药物戒断。我们将招募60名受试者,
未经治疗的OUD和最近的芬太尼使用通过宾夕法尼亚大学的研究中心,
成瘾受试者将被随机分配至两组之一:标准启动,受试者将开始
一旦使用临床阿片类药物出现中度阿片类药物戒断,则在禁欲> 8小时后使用丁丙诺啡
戒断量表(COWS)至少11;或一种新的低剂量("微剂量")方法,
COWS <4且丁丙诺啡剂量在10小时内递增,未持续使用完全激动剂
阿片类药物我们将比较每种方法的成功率,"成功"定义为达到每日总
8mg丁丙诺啡剂量,COWS从基线增加> 6,且未提前终止
任何原因这项研究的结果将用于支持R01应用程序,以测试这种新方法
在现实世界中开始丁丙诺啡,门诊设置有较大样本的未经治疗的个体
OUD。这种方法具有广泛的应用,以增加获得办公室为基础的治疗OUD。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KYLE Matthew KAMPMAN其他文献
KYLE Matthew KAMPMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KYLE Matthew KAMPMAN', 18)}}的其他基金
Combining Pregabalin with Lofexidine: Can it Increase the Success of Transition to Naltrexone?
普瑞巴林与洛非西定联合使用:能否提高纳曲酮过渡的成功率?
- 批准号:
10832720 - 财政年份:2019
- 资助金额:
$ 23.28万 - 项目类别:
Pharmacogenetic Study of Opioid Agonist Treatments in MVP
阿片类激动剂治疗 MVP 的药物遗传学研究
- 批准号:
9890783 - 财政年份:2019
- 资助金额:
$ 23.28万 - 项目类别:
Remote observed dosing to improve Suboxone compliance in clinical practice
远程观察给药以提高临床实践中的 Suboxone 依从性
- 批准号:
9982921 - 财政年份:2018
- 资助金额:
$ 23.28万 - 项目类别:
Remote observed dosing to improve Suboxone compliance in clinical practice
远程观察给药以提高临床实践中的 Suboxone 依从性
- 批准号:
9754094 - 财政年份:2018
- 资助金额:
$ 23.28万 - 项目类别:
Center for the Development of Novel Medications for Cocaine Dependence
可卡因依赖新药开发中心
- 批准号:
8925041 - 财政年份:2014
- 资助金额:
$ 23.28万 - 项目类别:
Center for the Development of Novel Medications for Cocaine Dependence
可卡因依赖新药开发中心
- 批准号:
8846714 - 财政年份:2014
- 资助金额:
$ 23.28万 - 项目类别:
2/2 Multicenter trial of combined pharmacotherapy to treat cocaine dependence
2/2 联合药物疗法治疗可卡因依赖的多中心试验
- 批准号:
8439392 - 财政年份:2013
- 资助金额:
$ 23.28万 - 项目类别:
2/2 Multicenter trial of combined pharmacotherapy to treat cocaine dependence
2/2 联合药物疗法治疗可卡因依赖的多中心试验
- 批准号:
8639514 - 财政年份:2013
- 资助金额:
$ 23.28万 - 项目类别:
2/2 Multicenter trial of combined pharmacotherapy to treat cocaine dependence
2/2 联合药物疗法治疗可卡因依赖的多中心试验
- 批准号:
8814192 - 财政年份:2013
- 资助金额:
$ 23.28万 - 项目类别:
Multisite Controlled Trial of Cocaine Vaccine (4 of 6) Philadelphia Treatment Sit
可卡因疫苗多中心对照试验(第 4 次,共 6 次)费城治疗中心
- 批准号:
8277544 - 财政年份:2008
- 资助金额:
$ 23.28万 - 项目类别:
相似海外基金
StuDy AimED at Increasing AlCohol AbsTinEnce (DEDICATE)
旨在提高酒精戒断率的研究(奉献)
- 批准号:
10577022 - 财政年份:2023
- 资助金额:
$ 23.28万 - 项目类别:
A Controlled Study of Extended Cannabis Abstinence in Major Depression
重度抑郁症患者长期吸食大麻的对照研究
- 批准号:
478313 - 财政年份:2023
- 资助金额:
$ 23.28万 - 项目类别:
Operating Grants
Exercised-induced modulation of insular cortex microcircuitry during alcohol abstinence
戒酒期间运动诱导的岛叶皮质微电路调节
- 批准号:
10748763 - 财政年份:2023
- 资助金额:
$ 23.28万 - 项目类别:
Prapela™ SVS: A cost-effective stochastic vibrotactile stimulation device toimprove the clinical course of infants with neonatal abstinence syndrome.
Prapela™ SVS:一种经济高效的随机振动触觉刺激装置,可改善患有新生儿戒断综合征的婴儿的临床过程。
- 批准号:
10837421 - 财政年份:2023
- 资助金额:
$ 23.28万 - 项目类别:
Enforced alcohol abstinence: does it reduce reoffending?
强制戒酒:会减少再犯罪吗?
- 批准号:
ES/X003566/1 - 财政年份:2023
- 资助金额:
$ 23.28万 - 项目类别:
Fellowship
Neurobiological impact of acute digital media abstinence among drug using college students
吸毒大学生急性数字媒体戒断的神经生物学影响
- 批准号:
10677380 - 财政年份:2023
- 资助金额:
$ 23.28万 - 项目类别:
Single-cell whole brain imaging of nicotine intoxication, dependence, and abstinence
尼古丁中毒、依赖和戒断的单细胞全脑成像
- 批准号:
10588509 - 财政年份:2023
- 资助金额:
$ 23.28万 - 项目类别:
Understanding recovery from alcohol use disorder: Longitudinal observation of two voluntary temporary abstinence periods
了解酒精使用障碍的恢复:两个自愿临时戒酒期的纵向观察
- 批准号:
10740677 - 财政年份:2023
- 资助金额:
$ 23.28万 - 项目类别:
Sleep Disturbances During Cocaine Abstinence, Dopamine Adaptations, and Motivation for Cocaine
可卡因戒断期间的睡眠障碍、多巴胺适应和可卡因动机
- 批准号:
10681668 - 财政年份:2023
- 资助金额:
$ 23.28万 - 项目类别:
Transcriptional adaptations driving the intensification of alcohol-seeking in dependent rats undergoing prolonged abstinence
转录适应导致长期戒酒的依赖性大鼠对酒精的渴求加剧
- 批准号:
10540014 - 财政年份:2022
- 资助金额:
$ 23.28万 - 项目类别: